Strategas Macro Momentum ETF (SAMM)
| Assets | $25.67M |
| Expense Ratio | 0.66% |
| PE Ratio | 23.48 |
| Shares Out | 850,000 |
| Dividend (ttm) | $0.31 |
| Dividend Yield | 1.03% |
| Ex-Dividend Date | Dec 30, 2025 |
| Payout Frequency | Annual |
| Payout Ratio | 23.60% |
| Volume | 2,441 |
| Open | 29.97 |
| Previous Close | 30.19 |
| Day's Range | 29.90 - 30.15 |
| 52-Week Low | 21.88 |
| 52-Week High | 31.68 |
| Beta | n/a |
| Holdings | 33 |
| Inception Date | Apr 3, 2024 |
About SAMM
Fund Home PageThe Strategas Macro Momentum ETF (SAMM) is an exchange-traded fund that mostly invests in total market equity. The fund primarily invests in 20-50 US equities selected through a tactical, macro momentum approach that looks for strong technical, momentum, and relative strength characteristics. The actively managed fund aims for a more defensive posture when the indicators turn negative. SAMM was launched on Apr 3, 2024 and is issued by Strategas.
Top 10 Holdings
40.34% of assets| Name | Symbol | Weight |
|---|---|---|
| Cash | n/a | 4.53% |
| APA Corporation | APA | 4.28% |
| Amgen Inc. | AMGN | 4.16% |
| Parker-Hannifin Corporation | PH | 4.08% |
| Gilead Sciences, Inc. | GILD | 4.04% |
| Marriott International, Inc. | MAR | 3.95% |
| Keysight Technologies, Inc. | KEYS | 3.90% |
| GE Vernova Inc. | GEV | 3.89% |
| Regeneron Pharmaceuticals, Inc. | REGN | 3.85% |
| Eli Lilly and Company | LLY | 3.67% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 30, 2025 | $0.3106 | Jan 7, 2026 |
| Dec 30, 2024 | $0.1904 | Jan 7, 2025 |
Performance
SAMM had a total return of 21.72% in the past year, including dividends. Since the fund's inception, the average annual return has been 11.64%.
News
Strategas Lists SAMM, a Tactical ETF with an Active Approach to Macro & Momentum Investing
NEW YORK--(BUSINESS WIRE)--Strategas Asset Management announces the launch of Strategas Macro Momentum ETF (SAMM), its third in a suite of thematic, actively managed ETFs.